A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia ® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)

Condition:   Postmenopausal Women With Osteoporosis Interventions:   Drug: MB09 (denosumab biosimilar);   Drug: EU-Prolia;   Dietary Supplement: Elemental Calcium;   Dietary Supplement: Vitamin D Sponsor:   mAbxience S.A Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials